Lysate News and Research

RSS

Avioq receives premarket approval from FDA for Avioq HIV-1 Microelisa System

Avioq, Inc. announced it has received premarket approval from the U.S. Food and Drug Administration (FDA) for the Avioq HIV-1 Microelisa System.

1 Dec 2009

TAP delivers customized automated protein purification system in collaboration with a European major

The Automation Partnership (TAP), a world leader in the design and development of innovative automation for life science applications, today announced its Advanced Projects Group has successfully collaborated with a major European antibody therapeutics company to deliver a custom automated protein purification and concentration system helping the company accelerate its pre-clinical research.

24 Nov 2009

Initiation of Phase I/IIa clinical trial of IL-7 announced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa clinical trial of IL-7 in support of tumor lysate/KLH pulsed dendritic cell vaccines in a pilot study of tumor vaccination in patients with metastatic or recurrent pediatric solid tumors and altered T cell homeostasis, including patients with Ewing’s sarcoma family of tumors (ESFT), rhabdomyosarcoma, neuroblastoma, synovial cell sarcoma, desmoplastic small round cell tumor, undifferentiated sarcoma, and embryonal sarcoma.

23 Nov 2009

Viral protein could be a major player in SARS virulence

Ever since the previously unknown SARS virus emerged from southern China in 2003, University of Texas Medical Branch at Galveston virologists have focused on finding the source of the pathogen's virulence - its ability to cause disease. In the 2003 epidemic, for example, between 5 and 10 percent of those who fell sick from the SARS virus died, adding up to more than 900 fatalities worldwide.

30 Oct 2009

Soviet-developed immune formula boosts immune activity

A recent study on an American-made, Soviet-developed immune formula shows the product has a significant effect on immune function.

19 Nov 2008

Immunotherapy shows promise in high-risk pediatric sarcomas

Based on a pilot study in children with sarcoma, researchers at the National Institutes of Health (NIH) believe that immunotherapy could prove beneficial in treating high-risk forms of this cancer.

3 Aug 2008